Uniqure NV

QURE remains in a high‐conviction Stage 2 advance underpinned by a Momentum Breakout, with clear higher highs and higher lows and price riding well above rising EMAs. Both long‐ and medium‐term directional biases are bullish, but current extreme overbought readings and significant extension above the 9/21/50 EMAs argue against immediate entry. The optimal engagement is to Stalk, awaiting a pullback into the rising EMAs or prior consolidation zone for a higher‐probability buy.

• ↑AMT-130 delivered a 75% slowdown in Huntington’s disease progression over three years.
• ↑Breakthrough therapy designation and MHRA engagement accelerate approval path.
• ↓Revenues fell from $16.1M in Q4 2025 to $3.6M in Q1 2026.